China
Africa
Explore chapters and articles related to this topic
COVID-19 Pandemic and Traditional Chinese Medicines
Published in Hanadi Talal Ahmedah, Muhammad Riaz, Sagheer Ahmed, Marius Alexandru Moga, The Covid-19 Pandemic, 2023
Roheena Abdullah, Ayesha Toor, Hina Qaiser, Afshan Kaleem, Mehwish Iqtedar, Tehreema Iftikhar, Muhammad Riaz, Dou Deqiang
The treaties on exogenous febrile and miscellaneous diseases contain Shegan mahuang decoction, Maxiang shigan decoction, Xiao cai hu decoction and Wuling powder as classic prescriptions that are combined to make Qingfei paidu decoction. Qingfei paidu decoction constitutes a total of 21 herbs that are Asari Radix et Rhizoma (xixin), Atractylodis Macrocephalae Rhizoma (baizhu), Belamcandae Rhizoma (shegan), Asteris Radix (ziwan), Armeniacea Semen (xingren), Aurantii Fructus Immaturus (zhishi), Ephedrae Herba (mahuang), processed Glycyrrhizae Radix et Rhizoma (zhigacao), Dioscoreae Rhizoma (shanyao), Pinelliae Rhizoma Praeparatum Cum Zingibere et Alumine (jiang banxia), Citri reticulatae Pericarpium (chenpi), Gypsum Fibrosum (sheng shigao), Alismatis Rhizoma (zexie), Pogostemonis Herba (huoxiang), Polyporus (zhuling), Bupleuri Radix (chaihu), Poria (fuling), Farfarae Flos (donghua), Cinnamomi Ramulus (guizhi), Zingiberis Rhizoma Recens (shengjiang) and Scutellariae Radix (huanqing) [19, 31].
Low Back Pain
Published in Benjamin Apichai, Chinese Medicine for Lower Body Pain, 2021
Modifications: With more wind damp symptoms, add Fang Ji 防己, Qin Jiao 秦艽, Zhi Fu Zi 附子, Wu Tou 烏頭.With effusion in lower limb joints, add Niu Xi 牛膝.With Qi stagnation, add Chen Pi 陳皮and Mu Xiang 木香.With blood deficiency, add Dang Gui 當歸 and Bai Shao 白芍.
Decontextualised Chinese medicines
Published in Vivienne Lo, Michael Stanley-Baker, Dolly Yang, Routledge Handbook of Chinese Medicine, 2022
Michael Heinrich, Ka Yui Kum, Ruyu Yao
In addition, a multi-herbal preparation is registered in Germany, which originally came from Japan. The registered medicine is based on a formulation – Rikkunshito – defined in the Japanese Pharmacopoeia (JP 2017), and in Europe it is indicated for the relief of mild gastrointestinal disorders, such as loss of appetite, malaise and bloating. It contains defined quantities of eight drugs: rootstock of Panax ginseng C.A.Mey. – Renshen 人參;rootstock of Atractylodes lancea (Thunb.) DC. – Cangzhu 蒼朮 (as Atractylodes japonica);fruiting body of Wolfiporia extensa (Peck) Ginns – Fuling 茯苓 (syn. Poria cocos F.A.Wolf);rhizome of Pinellia ternata (Thunb.). – Banxia 半夏Makino;fruit peel of Citrus deliciosa Ten. – Chenpi 陳皮 (Unshiu);fruit of Ziziphus jujuba Mill. – Dazao 大棗;rootstock of Glycyrrhiza glabra L. – Gancao 甘草 and related spp.;rootstock of Zingiber officinale Roscoe. – Shengjiang 生薑.
In silico and in vivo demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD
Published in Annals of Medicine, 2023
Chong Peng, Jing Li, Xuehong Ke, Fengbin Liu, Ke-er Huang
Qi-Ge decoction (QGD) is a prescription that originated from the ‘Zhengzhihuibu’, which was written by Yongzi Li during the Qing Dynasty of China in 1687 AD. QGD comprises Astragalus membranaceus (Fisch.) (Huangqi) and Puerariae lobatae radix (Gegen) in combination with Citrus reticulata blanco (Rutaceae) (Chenpi). In clinical practice, QGD is widely used because of its various medicinal properties. It contains multiple active compounds, including flavonoids, polysaccharides and triterpenoids, that have been shown to have anti-inflammatory, antioxidant and hepatoprotective effects in preclinical and clinical studies. It is commonly used to treat fatty liver diseases (alcoholic or nonalcoholic) and gastric mucosal injury and to protect against acute liver injury caused by carbon tetrachloride. Additionally, some studies have found that it has efficacy in treating diseases of abnormal glucose and lipid metabolism, including diabetes and hyperlipidemia, in vivo [7,8]. However, the effects of QGD on NAFLD-induced dyslipidemia and hepatic steatosis are not fully understood. Additionally, Chinese formulas such as QGD often exert their pharmacological effects through multiple targets and a large number of signaling pathways, making it challenging to unravel the underlying mechanism of action [9,10]. As a result, researchers using traditional pharmacological methods may find it difficult to systematically analyze the effects of QGD on NAFLD-induced dyslipidemia and hepatic steatosis. Further research is needed to fully understand the mechanism of action of QGD in NAFLD.
LC-MS/MS detection of citrus unshiu peel-derived flavonoids in the plasma and brain after oral administration of yokukansankachimpihange in rats
Published in Xenobiotica, 2019
Mikina Takiyama, Takashi Matsumoto, Junko Watanabe
Yokukansankachimpihange (YKSCH) is a traditional Japanese Kampo medicine composed of nine crude drugs. In other words, it is a prescription that combines Citrus unshiu peel (CUP, Chimpi in Japanese) and Pinellia tuber (PT, Hange in Japanese) with yokukansan (YKS), which consists of seven crude drugs (see the Materials and Methods section for composition details). Both YKSCH and YKS are indicated for the treatment of neurosis and insomnia, as well as night crying and irritability in children, and all four indications have been approved by the Japanese Ministry of Health, Labor, and Welfare (MHLW). Recently, these Kampo medicines have been expected to treat the behavioral and psychological symptoms of dementia (BPSD), such as excitement, aggression, hallucination, insomnia, and anxiety (Aizawa et al., 2002; Hyde et al., 2017; Matsuda et al., 2013; Nagata et al., 2012). CUP and PT are known to improve gastrointestinal symptoms such as anorexia, in addition to stomachic and antiemetic effects (Kasahara et al., 1983, Lyu & Lee, 2013; Niijima et al., 1993). Therefore, YKSCH is supposed to be suitable for patients with dementia who have chronic symptoms due to reduced gastrointestinal function and comparatively lower physical strength (Hamaguchi et al., 2017).
Liuweibuqi capsules improve pulmonary function in stable chronic obstructive pulmonary disease with lung-qi deficiency syndrome by regulating STAT4/STAT6 and MMP-9/TIMP-1
Published in Pharmaceutical Biology, 2019
Dan-Dan Shen, Zhong-Hui Yang, Ji Huang, Fei Yang, Zi-Wei Lin, Ying-Fei Ou, Min-Hao Hu
Oral Huangqi, an ingredient of LWBQ capsules as well as a primary herb for strengthening Qi, exercises its beneficial effects in lung function improvement, life quality, and also in decreasing the incidence of exacerbations for patients with stable COPD (Wu et al. 2013). An et al. (2011) proved that Ginseng formulae (the ingredient of LWBQ capsules) also showed promising effects on lung functions along with an improved quality of life for patients with stable COPD. In addition, Chenpi (the ingredient of LWBQ capsules) has been reported to protect against wheezing, dyspnea, and cough, and consequently relieving asthma, a respiratory disease, using a cough guinea pig model induced by citric acid and an experimental asthma guinea pig model induced by histamine (Shi et al. 2009). A clinical study manifested that over-exposure to various exogenous pathogenic factors, which further causes impairment of lung qi and lung deficiency as well as yin-yang disharmony, accounts for the increasing incidence of COPD, while TCM therapy for COPD always conforms to the principles of eliminating the causative agent and enhancing the bodily constitution (Dong et al. 2014). Furthermore, Wang and colleagues (2017b) attested that LWBQ capsules could mitigate the progression of COPD by inhibiting the inflammatory response upon regulation of the JAK/STAT pathway in a COPD rat model.